Gene Green: “This has been an ongoing discussion between whatever agency we call it in Texas and the EPA.”

If the administration cares about accountability for 340B, perhaps they should start with implementing the delayed regulatory guidance program.

I look forward to hearing from our panelists regarding their experience with MIPS and recent changes made by Congress.

Critically, MACRA encourages providers to move away from fee-for-service and participate in a new delivery model that will reduce costs while increasing quality.

The 340B Drug Pricing Program was created by Congress in 1992. It helps safety net providers care for their most vulnerable patients and afford drugs that would otherwise be out of reach.